'Plumpness is healthier than being too thin'... Specialist warns against 'blind faith' in Wegovy

An endocrinologist has cautioned against the widespread use of popular weight-loss medications such as Wegovy and Mounjaro, particularly when prescribed for cosmetic reasons to individuals who are already within a normal weight range. Dr. Lee Jae-hyuk expressed strong concerns during an appearance on the YouTube channel 'Kim Jae-won TV,' stating that the long-term effects of these drugs on people with normal BMIs are not well-documented.

“

The mortality rate does not continue to decrease even if you lose weight. After a certain point, the mortality rate starts to increase again.

Dr. Lee cited recent studies suggesting that individuals with a Body Mass Index (BMI) between 25 and 26, classified as mildly overweight, may experience lower mortality rates compared to those with BMIs between 18 and 22, traditionally considered normal weight. This finding challenges conventional notions of healthy weight and has sparked debate about standard BMI classifications. However, Dr. Lee emphasized that maintaining an appropriate weight remains vital for preventing metabolic diseases like diabetes, even if slightly higher BMIs correlate with lower mortality.

“

Recent studies show that people with mild overweight (BMI of 25-26) have lower mortality rates. The mortality rate of thin people, previously considered within the normal range (BMI 18-22), is actually higher, leading to much discussion about the criteria for normal weight.

The physician specifically warned about the risks associated with using these potent drugs without comprehensive medical supervision. He highlighted the potential for significant muscle loss, with more than half of the weight lost being muscle mass, leading to a weakened state. Furthermore, he cautioned that discontinuing the medication often results in rapid weight regain, commonly known as the yo-yo effect, accompanied by accelerated facial aging and a decline in physical stamina. Dr. Lee recommended focusing on managing fructose intake and engaging in strength training as key strategies for reducing visceral fat and boosting metabolism.

“

These drugs have no large-scale experience of long-term use in people with normal weight. It is foolish to use them while bearing the burden of not knowing what might happen to me.